CORDIS · 305707 · FP7
RESOLVE A systems biology approach to RESOLVE the molecular pathology of two hallmarks of patients with metabolic syndrome and its co-morbidities; hypertriglyceridemia and low HDL-cholesterol
Coordinator: ACADEMISCH ZIEKENHUIS GRONINGEN (NL)
Through combining basic pre-clinical and clinical research, network analysis and computational modelling, RESOLVE aims at resolving the disturbed dynamics and mechanisms underlying the high triglyceride (HTG) and low high-density lipoprotein cholesterol (HDL-C) phenotype and insulin resistance in patients with metabolic syndrome (MetS) and its associated co-morbidities (cardiovascular disease, CVD; type 2 diabetes, T2DM; non-alcoholic fatty liver disease, NAFLD). RESOLVE will deliver on 6 specific objectives:i) build a computational model for analyzing the kinetics of plasma lipids, lipoprote…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
EU contribution: €10.5M awarded to the consortium. The project runs over approximately 5.5 years from 2013-01-01 to 2018-06-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from NL
see all →- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · H2020 · €92.5M
- GN5-2 — GN5-2101194278 · HORIZON · €80.0M
- GN4-3 — Horizon 2020: H2020-SGA-INFRA-GEANT-2018 (Topic [a] Research and Education Networking)856726 · H2020 · €77.5M
- GN4-2 — GN4-2 Research and Education Networking - GÉANT731122 · H2020 · €59.0M
- GN5-1 — GN5-1101100680 · HORIZON · €55.0M
- BIGPICTURE — Central Repository for Digital Pathology945358 · H2020 · €32.3M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the CP-IP funding scheme.
- What is the EU contribution?
- The European Commission contributes €10.5M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by ACADEMISCH ZIEKENHUIS GRONINGEN (NL).
- What is the project timeline?
- The project runs from 2013-01-01 to 2018-06-30 — approximately 5.5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 305707.